ORCHPHARMA

Feb 28 (Reuters) - Orchid Pharma Ltd ORCD.NS:

• GETS TAX ORDER WITH TAX LIABILITY OF 8 MILLION RUPEES

Source text: ID:nBSE610msz

Further company coverage: ORCD.NS

(([email protected];;))

** India's Orchid Pharma ORCD.NS locked in 5% upper circuit for fourth consecutive session

** Stock up 23.7% in five days, on course for longest winning streak of 2025

** Company's Alathur API facility successfully completed US FDA inspection, remains India's only US regulator-approved facility for antibiotic drug Sterile Cephalosporins, it said after market hours on February 19

** Stock still down around 28% so far in February on poor Q3 earnings and overall weakness in pharma .NIPHARM stocks

** API and formulations maker down 44% so far in 2025 vs 13.5% drop in .NIPHARM

(Reporting by Vivek Kumar M)

(([email protected];))

** Shares of Orchid Pharma ORCD.NS rise 3% to 860 rupees

** The pharma co said US FDA completed inspection at its Alathur, Tamil Nadu API facility, which resulted in seven minor observations, none of which pertain to the data integrity of the

facility

** Adds, facility also secures EU GMP certificate renewal for Cephalosporin API manufacturing

** Stock down 11% so far this week

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

Feb 19 (Reuters) - Orchid Pharma Ltd ORCD.NS:

• ORCHID PHARMA LTD - ALATHUR API FACILITY SUCCESSFULLY COMPLETES USFDA INSPECTION

• ORCHID PHARMA LTD - SECURES EU GMP CERTIFICATE RENEWAL FOR CEPHALOSPORIN API MANUFACTURING

• ORCHID PHARMA LTD - USFDA INSPECTION RESULTS IN SEVEN MINOR OBSERVATIONS

Source text: [ID:]

Further company coverage: ORCD.NS

(([email protected];;))

** Orchid Pharma ORCD.NS tumbles 15.6% to 1,041.1 rupees

** Stock set for worst day since November 2020, with trading volumes 9x the 30-day avg

** Co posts 29% Y/Y fall in Q3 consolidated profit; net sales fell ~2%

** Sharp price correction in export markets offset volume growth, said analysts at Systematix Institutional Equities

** Adds cash burn in branded formulation business also hurt

** Stock eyes fifth straight session of falls, and has shed 42% so far this year

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

** Shares of active pharmaceutical ingredients maker Orchid Pharma ORCD.NS rise 4.8% to 1,522.35 rupees

** Co posts a 37.5% rise in Sept-qtr consolidated profit at 272.4 million rupees ($3.2 mln); income from ops rose 12%

** Avg rating of three analysts covering ORCD at "strong buy" vs "hold" for peers Natco Pharma NATP.NS and Poly Medicure PLMD.NS

** ORCD's median PT is at 1,710 rupees - LSEG data

** Stock up ~114% so far this year vs a 76% and 85% rise in NATP and PLMD

($1 = 84.3930 Indian rupees)

(Reporting by Dimpal Gulwani in Bengaluru)

(([email protected]))

Nov 11 (Reuters) - Orchid Pharma Ltd ORCD.NS:

• ORCHID PHARMA SEPT-QUARTER CONSOL PROFIT 272.4 MILLION RUPEES

• ORCHID PHARMA SEPT-QUARTER CONSOL INCOME FROM OPERATIONS 2.23 BILLION RUPEES

Source text: ID:nBSE78Pf4J

Further company coverage: ORCD.NS

(([email protected];))

Sept 3 (Reuters) - Orchid Pharma Ltd ORCD.NS:

• GOT NO-OBJECTION LETTERS FROM BSE, NSE FOR MERGER OF DHANUKA LABORATORIES WITH CO

Further company coverage: ORCD.NS

(([email protected];))

July 17 (Reuters) - Orchid Pharma Ltd ORCD.NS:

• REAPPOINTED MANISH DHANUKA AS MD

Further company coverage: ORCD.NS

(([email protected];))

** Shares of Orchid Pharma ORCD.NS up 8.1% at 1,080 rupees after rising up as much as 9.2%

** Co said it has received DCGI approval for its antibiotic drug combination of Cefepime and Enmetazobactam

** Adds, approval paves the way for launch of the advanced injectable therapy for patients in India

** Formulation is indicated for the treatment of complicated urinary tract infections - ORCD

** Avg rating of three analysts equivalent of "strong buy", median PT is 1,247 rupees - LSEG data

** Stock rose 46.7% in March quarter, its highest quarterly rise since March 2021

** Stock up 51.6% YTD

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

May 23 (Reuters) - Orchid Pharma Ltd ORCD.NS:

• INDIA'S ORCHID PHARMA - MARCH-QUARTER CONSOL PROFIT 329.6 MILLION RUPEES VERSUS 591.4 MILLION RUPEES

• ORCHID PHARMA - MARCH-QUARTER CONSOL INCOME FROM OPERATIONS 2.17 BILLION RUPEES VERSUS 2.1 BILLION RUPEES

Source text for Eikon: ID:nBSE8Lxm1F

Further company coverage: ORCD.NS

(([email protected];))

May 2 (Reuters) - Orchid Pharma Ltd ORCD.NS:

• ORCHID PHARMA - GOT TAX ORDER ASCERTAINING TOTAL REVENUE ABSTRACT OF 26.6 MILLION RUPEES

Source text for Eikon: ID:nNSE61D3Tv

Further company coverage: ORCD.NS

(([email protected];))

** Shares of Orchid Pharma ORCD.NS rise ~12% to 1,359.95 rupees, their highest since June 2021

** US FDA approves Orchid Pharma's "enmetazobactam" to treat urinary tract infections

** Co expects U.S. launch in next couple of quarters

** Stock last up 2.8%, set for best monthly gain since March 2021

** Stock up ~75% YTD after nearly doubling in value in 2023

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

Feb 23 (Reuters) - Orchid Pharma Ltd ORCD.NS:

• ORCHID PHARMA’S ‘EXBLIFEP’ RECEIVES USFDA APPROVAL

• PRODUCT IS EXPECTED TO BE LAUNCHED WITHIN NEXT COUPLE OF QTRS IN US MARKET

Source text for Eikon: ID:nNSE38cM3C

Further company coverage: ORCD.NS

(([email protected];;))

** Shares of Orchid Pharma ORCD.NS rise as much as 17.7% to 1,036.1 rupees, highest since June 25, 2021

** The pharma co reported a near four-fold surge in Q3 consolidated profit, income from ops up 38% Y/Y

** Stock set to log gains for fourth consecutive session, if trend holds

** More than 1.1 mln shares change hands, 4.5x its 30-day avg

** ORCD trading above its 50-day, 100-day and 200-day simple moving averages since November

** Stock up 21% for the week, on track for biggest weekly gain since April 8, 2022

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

Feb 8 (Reuters) - Orchid Pharma Ltd ORCD.NS:

• DEC-QUARTER CONSOL PROFIT 294.3 MILLION RUPEES VERSUS 75.9 MILLION RUPEES YEAR AGO

• DEC-QUARTER CONSOL INCOME FROM OPERATIONS 2.21 BILLION RUPEES VERSUS 1.6 BILLION RUPEES YEAR AGO

Source text for Eikon: ID:nBSE7067bK

Further company coverage: ORCD.NS

(([email protected];))

** Shares of Orchid Pharma ORCD.NS hit upper circuit, up 20% at 863.85 rupees

** Stock set for best day since Sept. 21, 2017, if trend holds

** Drugmaker gets European Medicines Agency approval for antibiotic 'Exblifep'

** Stock sees busiest day since Dec. 8 when brokerage Investec initiated coverage of co

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

Jan 29 (Reuters) - Orchid Pharma Ltd ORCD.NS:

• EXBLIFEP GRANTED EUROPEAN MEDICINES AGENCY APPROVAL

Source text for Eikon: ID:nNSEDpPdf

Further company coverage: ORCD.NS

(([email protected];))

** Nuvama Institutional Equities initiates coverage on Orchid Pharma Ltd ORCD.NS with 'buy' rating, 12-month PT of 900 rupees

** Co shares hit a high of 7.4% to 734.50 rupees for the day, last up 3.6%

** Says new promoters have deleveraged balanced sheet and trebled EBITDA; co poised for growth on expanded capabilities, timely execution of opportunities and production linked incentives

** Adds management laserfocused on introducing products, expanding customer base, ratcheting up expanded capacity utilisation

** This should drive profit after tax compound annual growth rate of 49% over FY23–26E - Nuvama

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

** Shares of Orchid Pharma ORCD.NS surge as much as 20% to 679.30 rupees apiece, highest since July 7, 2021

** Stock rises after Investec initiates coverage of the drugmaker with a "buy" recommendation

** Investec sets target price at 800 rupees, an implied upside of 42.3%

** Adds ORCD is set for strong growth over the next three years as new management continues to execute the turnaround strategy well

** Co leveraging core strengths in key active pharma ingredients (APIs)-like anti-microbials such as Cephalosporin, notes Investec

** Estimates 35%+ compound annual growth rate (CAGR) in earnings before interest, taxes, depreciation and amortisation (EBITDA) over fiscal 2023-2026

** Stock seeing its most active session ever, with a trading volume of 1.6 mln shares, 18.3 times the 30-day avg - LSEG data

** Including session's gains, ORCD stock up 82% in 2023 so far

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

Dec 6 (Reuters) - Orchid Pharma Ltd ORCD.NS:

• APPROVED DRAFT SCHEME OF AMALGAMATION AND ARRANGEMENT BETWEEN DHANUKA LABORATORIES, CO

Source text for Eikon: ID:nBSE4TYfVH

Further company coverage: ORCD.NS

(([email protected];;))

Sept 12 (Reuters) - Orchid Pharma Ltd ORCD.NS:

• ENTERED INTO MANUFACTURING SUBLICENSE AGREEMENT WITH GLOBAL ANTIBIOTIC RESEARCH & DEVELOPMENT PARTNERSHIP

• AGREEMENT TO MANUFACTURE CEFIDEROCOL, AN ANTIBIOTIC TO TREAT CERTAIN GRAM-NEGATIVE INFECTIONS

Source text for Eikon: ID:nBSE3FZshw

Further company coverage: ORCD.NS

(([email protected];;))

Aug 10 (Reuters) - Orchid Pharma Ltd ORCD.NS:

• INDIA'S ORCHID PHARMA JUNE-QUARTER CONSOL PROFIT 94 MILLION RUPEES VERSUS LOSS 150.1 MILLION RUPEES

• ORCHID PHARMA JUNE-QUARTER CONSOL INCOME FROM OPERATIONS 1.83 BILLION RUPEES VERSUS 1.31 BILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: ORCD.NS

(([email protected];;))

July 11 (Reuters) - Orchid Pharma Ltd ORCD.NS:

• ENTERED INTO TECHNOLOGY TRANSFER AGREEMENT WITH BIOTECHLOGY CO FOR IT'S FERMENTATION BASED 7ACA PROJECT UNDER PLI SCHEME

Source text for Eikon: ID:nNSEc0qYj9

Further company coverage: ORCD.NS

(([email protected];))

** Shares of Orchid Pharma Ltd ORCD.NS rise as much as 5% to 470 rupees, their highest since August 2021

** Drug maker posts its biggest intraday pct gain since May 11

** Stock trading above its 50-, 100-, and 200-day exponential moving averages since June 1

** Relative Strength Index (RSI) crossed over the upper limit of 70, indicating that the stock is overbought

** About 25,728 shares change hands by 9:49 a.m. IST, 2.2x the 30-day avg - Refinitiv Data

** If trends hold, stock on track to advance for second consecutive session

** Moving Average Convergence Divergence (MACD) line of the stock has been over the signal line for five sessions, suggesting bullish bias

** Stock up ~23% YTD as of last close

(Reporting by Priya Sagar in Bengaluru)

(([email protected]))